Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Establishes joint lab to develop full continuous processing for the manufacture of monoclonal antibodies
November 3, 2017
By: Kristin Brooks
Managing Editor, Contract Pharma
WuXi Biologics and its partner Pall Corp., a provider of advanced filtration, separation and purification technologies, established a joint lab to develop full continuous processing for the manufacture of monoclonal antibodies (mAb). The three-year project started with the continuous operation of individual processes and will gradually be expanded to downstream processing development and production. The joint lab will serve WuXi Biologics’ customers and aims to significantly reduce mAb drugs’ manufacturing costs. The joint lab, constructed with Pall’s Cadence Continuous Bioprocess System and integrated with its single-use technology platform, provides process flexibility, facilitates switches between processes and helps to avoid cross-contamination. The platform helps pharma companies reduce the manufacturing space required at a facility and costs. WuXi Biologics has developed high-yielding cell lines and lab-scale continuous processes, significantly increasing the expression of some mAbs to up to equivalent of 40-50 g/L in the traditional fed-batch process, which is approximately 10 times more productive than the typical fed-batch process. Moving forward, the teams will work to improve large-scale purification equipment and technology that often becomes a bottleneck in continuous processing. With this joint lab, WuXi plans to expand the continuous process scale to 500 L and reduce mAb manufacturing cost to $30-50/g, and then scale up to 1000 L and further reduce costs to less than $15/g. “Pall offers complete process development, as well as equipment and technical support needed for continuous bio-manufacturing solutions that reduce costs for biopharmaceutical process development and production, and that enhance core competencies for biopharmaceutical companies. We’re excited about this new partnership with WuXi Biologics, they have a strong global influence which will help accelerate the development and innovation of advanced bioprocesses,” said Jennifer Honeycutt, president of Pall Corp. “WuXi Biologics is committed to further accelerating our expansion in capabilities and capacities, strengthening our leadership position as the most comprehensive and integrated enabling platform, empowering anyone and any company to discover, develop and manufacture biologics,” said Dr. Chris Chen, chief executive officer of WuXi Biologics. “The partnership with Pall helps us utilize the global innovation and leading technology to effectively resolve bottlenecks of continuous processing, to significantly lower the cost of biologics and benefits patients worldwide.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !